---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-083462"
form_type: "8-K"
ticker: "IKT"
cik: "0001750149"
company_name: "Inhibikase Therapeutics, Inc."
filed_at: "2022-03-24T23:59:59+00:00"
generated_at: "2026-06-26T18:36:57.724505+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "low"
source: SEC EDGAR
---

# Inhibikase presents Phase 1/1b data at AD/PD 2022; no numerical results in 8-K

## Summary
- Company presented Phase 1 and 1b clinical study results at AD/PD Conference in Barcelona on March 18, 2022.
- Presentation focuses on Abl-kinase inhibition (IKT-148009) for Parkinson's disease modification.
- No specific quantitative outcomes, milestones, or financial impact disclosed in the filing.

## SEC filing metadata
- accession: 0001193125-22-083462
- form_type: 8-K
- ticker: IKT
- cik: 0001750149
- company_name: Inhibikase Therapeutics, Inc.
- filed_at: 2022-03-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750149/000119312522083462/0001193125-22-083462-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750149/000119312522083462/d320841d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-083462
- JSON: https://secwatch.observer/filing/0001193125-22-083462.json
- Plain text: https://secwatch.observer/filing/0001193125-22-083462.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.